@article{5814ac2c131746b2a1440f20e67cc60d,
title = "Immunotherapy trials in mesothelioma — promising results, but don{\textquoteright}t stop here",
author = "Nowak, {Anna K.} and Forde, {Patrick M.}",
note = "Funding Information: The research of A.K.N. is supported by the National Health and Medical Research Council Centre for Research Excellence Grant. Funding Information: A.K.N. has been a paid consultant or adviser for Bayer, Boehringer Ingelheim, MSD and Roche; has been a consultant or adviser with fees to her institution for Atara, Douglas and Pharmabcine; has received travel funding from AstraZeneca and Boehringer Ingelheim; and her institution receives research funding to institution from AstraZeneca and Douglas Pharmaceuticals. P.M.F. has been an unpaid consultant or adviser for Abbvie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb (BMS), EMD Serono, Inivata, Janssen, Merck and Novartis, and his institution receives research funding from AstraZeneca, BMS, Corvus, Kyowa and Novartis.",
year = "2019",
doi = "10.1038/s41571-019-0291-4",
language = "English (US)",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
}